The results demonstrated that pIL-12 GET results in decreased levels of PD1 expression on CD4+ and CD8+ T cells, percentage of Treg cells in the tumor and increased infiltration of CD8+PD1− T cells leading to better control of tumor growth, strongly suggesting that therapy with pIL-12 GET has the potential to improve outcomes. Here, CD8A is linked to neoplasm.